Birth Size as a Determinant of Cardiometabolic Risk Factors in Children

Henrikki Nordman1, Jarmo Jääskeläinen2, Raimo Voutilainen2

  • 1Department of Pediatrics, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, hnordman@student.uef.fi.

Insights

Children born small (SGA) or large (LGA) for gestational age face increased cardiometabolic disease risk. Early growth patterns and later weight gain significantly influence this risk, highlighting the need for weight management interventions.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Health
  • Metabolic Syndrome Research

Background:

  • Birth size, including small for gestational age (SGA) and large for gestational age (LGA), is linked to later cardiometabolic disease risk.
  • While SGA's association with cardiovascular risk is established, LGA's impact remains debated.
  • Early postnatal growth and subsequent weight gain are critical factors influencing adult cardiometabolic health.

Purpose of the Study:

  • To explore the association between birth size (SGA and LGA) and cardiometabolic disease risk.
  • To investigate the role of early growth patterns and later weight gain in mediating this association.
  • To emphasize the importance of maintaining normal weight for reducing long-term cardiometabolic risk in SGA and LGA individuals.

Main Methods:

  • The study reviews existing literature on birth size, early growth trajectories, and adult cardiometabolic outcomes.
  • It analyzes the influence of catch-up (SGA) and catch-down (LGA) growth on health.
  • Risk factors such as overweight, obesity, glucose metabolism, dyslipidemia, hypertension, and inflammation are considered.

Main Results:

  • Both SGA and LGA birth sizes are associated with an increased risk of overweight and obesity, which often persists into adulthood.
  • Early compensatory growth in SGA and catch-down growth in LGA may contribute to adverse health outcomes.
  • Altered glucose metabolism, dyslipidemia, hypertension, and low-grade inflammation are linked to birth weight and are often related to overweight or adverse fat distribution.

Conclusions:

  • Maintaining a normal weight throughout life is crucial for mitigating cardiometabolic risk in individuals born SGA or LGA.
  • Effective interventions targeting weight management are needed for SGA and LGA children to reduce their long-term cardiometabolic risk.
  • Further research should focus on developing and implementing these interventions.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
172
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
723
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
148
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
21.9K